Immunome (NASDAQ:IMNM) Announces Earnings Results, Misses Estimates By $0.16 EPS

Immunome (NASDAQ:IMNM) announced its earnings results on Wednesday. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16), Zacks reports. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%.

Immunome Price Performance

Immunome stock opened at $8.57 on Thursday. The company has a market cap of $683.69 million, a price-to-earnings ratio of -1.06 and a beta of 1.93. Immunome has a one year low of $8.30 and a one year high of $26.70. The firm has a 50-day moving average of $9.84 and a 200-day moving average of $11.64.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

IMNM has been the topic of a number of research reports. Lifesci Capital began coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Monday, March 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has a consensus rating of “Buy” and a consensus target price of $27.17.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.